Healthpeak Properties, Inc. (BVMF:P1EA34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 69.50B +1.5% |
| Revenue (ttm) | 14.99B +2.7% |
| Net Income | 1.16B -20.5% |
| EPS | 1.66 -19.7% |
| Shares Out | n/a |
| PE Ratio | 60.11 |
| Forward PE | 124.98 |
| Dividend | 4.17 (4.23%) |
| Ex-Dividend Date | May 15, 2026 |
| Volume | 18 |
| Open | 101.10 |
| Previous Close | 98.70 |
| Day's Range | 100.50 - 101.10 |
| 52-Week Range | 80.48 - 105.49 |
| Beta | 0.98 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 5, 2026 |
About Healthpeak Properties
Healthpeak Properties, Inc. is a Standard & Poor’s 500 company that owns, operates, and develops high-quality real estate focused on healthcare discovery and delivery in the United States. Our company was originally founded in 1985. We are organized as an umbrella partnership REIT. We hold substantially all our assets and conduct our operations through our operating subsidiary, Healthpeak OP, a consolidated subsidiary of which we are the managing member. We are a Maryland corporation and qualify as a self-administered REIT. We are headquartered... [Read more]
Financial Performance
In 2025, Healthpeak Properties's revenue was $2.82 billion, an increase of 4.52% compared to the previous year's $2.70 billion. Earnings were $70.51 million, a decrease of -70.91%.
Financial numbers in USD Financial StatementsNews
Healthpeak Properties price target raised to $21 from $19 at Scotiabank
Scotiabank raised the firm’s price target on Healthpeak Properties (DOC) to $21 from $19 and keeps a Sector Perform rating on the shares. The firm is updating its estimates for…
Healthpeak Properties price target raised to $20 from $18 at Morgan Stanley
Morgan Stanley analyst Ronald Kamdem raised the firm’s price target on Healthpeak Properties (DOC) to $20 from $18 and keeps an Overweight rating on the shares.
Healthpeak Properties price target raised to $21 from $19 at Baird
Baird analyst Wesley Golladay raised the firm’s price target on Healthpeak Properties (DOC) to $21 from $19 and keeps an Outperform rating on the shares. The firm updated its model…
Healthpeak Properties price target raised to $19 from $17 at UBS
UBS raised the firm’s price target on Healthpeak Properties (DOC) to $19 from $17 and keeps a Neutral rating on the shares.
Healthpeak Properties price target raised to $20 from $17.50 at Citi
Citi raised the firm’s price target on Healthpeak Properties (DOC) to $20 from $17.50 and keeps a Neutral rating on the shares.
Healthpeak Properties downgraded to In Line from Outperform at Evercore ISI
Evercore ISI downgraded Healthpeak Properties (DOC) to In Line from Outperform with a price target of $21, up from $20. While the quarter was complicated by the Janus Living IPO…
Healthpeak Properties Q1 Earnings Call Highlights
Healthpeak Properties NYSE: DOC reported first-quarter 2026 adjusted funds from operations of $0.45 per share and raised its full-year FFO adjusted guidance after completing several major capital allo...
Healthpeak Properties Earnings Call Transcript: Q1 2026
Q1 2026 saw strong execution with the Janus Living IPO, robust leasing in all segments, and accretive capital actions. Guidance was raised as senior housing and outpatient medical outperformed, while life science occupancy and pipeline improved.
Healthpeak Properties Earnings release: Q1 2026
Healthpeak Properties released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
Healthpeak Properties Quarterly report: Q1 2026
Healthpeak Properties has published its Q1 2026 quarterly earnings report on May 6, 2026.
Healthpeak Properties Raises 2026 Earnings Guidance Following Completion of the Janus Living IPO, Accretive Capital Allocation, and Strong First Quarter 2026 Results
DENVER--(BUSINESS WIRE)--Healthpeak Properties, Inc. (NYSE: DOC), a leading owner, operator, and developer of real estate for healthcare discovery and delivery, today announced results for the quarter...
Healthpeak Properties Transcript: AGM 2026
The meeting achieved a 91% quorum, with all director nominees elected and both additional proposals approved. No questions were raised by shareholders, and final results will be filed with the SEC.
Healthpeak Properties price target lowered to $18 from $21 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Healthpeak Properties (DOC) to $18 from $21 and keeps an Overweight rating on the shares after updating the firm’s 2026 and 2027…
Healthpeak Properties initiated with a Neutral at UBS
UBS initiated coverage of Healthpeak Properties (DOC) with a Neutral rating and $17 price target The stable performance in outpatient medical and senior housing is being offset by ongoing weakness…
Healthpeak Properties initiated with a Neutral at UBS
UBS initiated coverage of Healthpeak Properties (DOC) with a Neutral rating and $17 price target The stable performance in outpatient medical and senior housing is being offset by ongoing weakness…
Janus Living initiated with a Buy at BofA
BofA initiated coverage of Janus Living (JAN) with a Buy rating and $29 price target. The pure-play senior housing REIT externally managed by Healthpeak Properties (DOC) has 100% NOI exposure…
Healthpeak Properties Announces Dates of First Quarter 2026 Earnings Release, Conference Call, and Webcast
DENVER--(BUSINESS WIRE)--Healthpeak Properties, Inc. (NYSE: DOC), a leading owner, operator, and developer of real estate for healthcare discovery and delivery, is scheduled to report first quarter 20...
Healthpeak Properties Declares Monthly Common Stock Cash Dividends for the Second Quarter of 2026
DENVER--(BUSINESS WIRE)--Healthpeak Properties, Inc. (NYSE: DOC), a leading owner, operator, and developer of real estate for healthcare discovery and delivery, announced that on April 6, 2026, its Bo...
Healthpeak Properties price target lowered to $19 from $20 at Baird
Baird analyst Wesley Golladay lowered the firm’s price target on Healthpeak Properties (DOC) to $19 from $20 and keeps an Outperform rating on the shares. The firm updated its model…
Citi cuts Healthpeak target, opens ‘upside 30-day catalyst watch’
Citi lowered the firm’s price target on Healthpeak Properties (DOC) to $17.50 from $18 and keeps a Neutral rating on the shares. Citi also opened an “upside 30-day catalyst watch”…
Zealand Pharma Establishes U.S. Research Hub in Cambridge, Massachusetts to Expand Drug Discovery Capabilities and Accelerate Medicine Creation
Press release – No. 6 / 2026 Zealand Pharma Establishes U.S. Research Hub in Cambridge, Massachusetts to Expand Drug Discovery Capabilities and Accelerate Medicine Creation New research hub in Cambrid...
Healthpeak Properties Closes New $400 Million Delayed-Draw Term Loan Facility
DENVER--(BUSINESS WIRE)--Healthpeak Properties, Inc. (NYSE: DOC) (“Healthpeak”), a leading owner, operator, and developer of real estate for healthcare discovery and delivery, announced today that it ...
Healthpeak Properties and Janus Living Announce Closing of Janus Living Initial Public Offering
DENVER--(BUSINESS WIRE)--Healthpeak Properties, Inc. (NYSE: DOC) (“Healthpeak”) and Janus Living, Inc. (NYSE: JAN) (“Janus Living”) announced today that Janus Living has completed its initial public o...
5 ‘Healthy' Dividends Paying Up To 14.1%
Healthcare dividend stocks are selling off with the turbulence in the Middle East.
Janus Living indicated to open at $23-$24, IPO priced at $20 per share
Healthpeak Properties (DOC) and Janus Living (JAN) announced the pricing of Janus Living’s upsized initial public offering of 42M shares of Janus Living Class A-1 common stock at a price…